IBDEI27C ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,36962,1,4,0)
 ;;=4^D49.4
 ;;^UTILITY(U,$J,358.3,36962,2)
 ;;=^5002274
 ;;^UTILITY(U,$J,358.3,36963,0)
 ;;=D49.5^^169^1864^10
 ;;^UTILITY(U,$J,358.3,36963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36963,1,3,0)
 ;;=3^Neoplasm of unspecified behavior of other genitourinary organs
 ;;^UTILITY(U,$J,358.3,36963,1,4,0)
 ;;=4^D49.5
 ;;^UTILITY(U,$J,358.3,36963,2)
 ;;=^5002275
 ;;^UTILITY(U,$J,358.3,36964,0)
 ;;=D49.6^^169^1864^6
 ;;^UTILITY(U,$J,358.3,36964,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36964,1,3,0)
 ;;=3^Neoplasm of unspecified behavior of brain
 ;;^UTILITY(U,$J,358.3,36964,1,4,0)
 ;;=4^D49.6
 ;;^UTILITY(U,$J,358.3,36964,2)
 ;;=^5002276
 ;;^UTILITY(U,$J,358.3,36965,0)
 ;;=D49.7^^169^1864^9
 ;;^UTILITY(U,$J,358.3,36965,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36965,1,3,0)
 ;;=3^Neoplasm of unspecified behavior of endo glands
 ;;^UTILITY(U,$J,358.3,36965,1,4,0)
 ;;=4^D49.7
 ;;^UTILITY(U,$J,358.3,36965,2)
 ;;=^5002277
 ;;^UTILITY(U,$J,358.3,36966,0)
 ;;=D49.81^^169^1864^13
 ;;^UTILITY(U,$J,358.3,36966,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36966,1,3,0)
 ;;=3^Neoplasm of unspecified behavior of retina and choroid
 ;;^UTILITY(U,$J,358.3,36966,1,4,0)
 ;;=4^D49.81
 ;;^UTILITY(U,$J,358.3,36966,2)
 ;;=^5002278
 ;;^UTILITY(U,$J,358.3,36967,0)
 ;;=D49.89^^169^1864^11
 ;;^UTILITY(U,$J,358.3,36967,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36967,1,3,0)
 ;;=3^Neoplasm of unspecified behavior of other specified sites
 ;;^UTILITY(U,$J,358.3,36967,1,4,0)
 ;;=4^D49.89
 ;;^UTILITY(U,$J,358.3,36967,2)
 ;;=^5002279
 ;;^UTILITY(U,$J,358.3,36968,0)
 ;;=D49.9^^169^1864^14
 ;;^UTILITY(U,$J,358.3,36968,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36968,1,3,0)
 ;;=3^Neoplasm of unspecified behavior of unspecified site
 ;;^UTILITY(U,$J,358.3,36968,1,4,0)
 ;;=4^D49.9
 ;;^UTILITY(U,$J,358.3,36968,2)
 ;;=^5002280
 ;;^UTILITY(U,$J,358.3,36969,0)
 ;;=D68.51^^169^1864^1
 ;;^UTILITY(U,$J,358.3,36969,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36969,1,3,0)
 ;;=3^Activated protein C resistance
 ;;^UTILITY(U,$J,358.3,36969,1,4,0)
 ;;=4^D68.51
 ;;^UTILITY(U,$J,358.3,36969,2)
 ;;=^5002358
 ;;^UTILITY(U,$J,358.3,36970,0)
 ;;=D68.52^^169^1864^16
 ;;^UTILITY(U,$J,358.3,36970,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36970,1,3,0)
 ;;=3^Prothrombin gene mutation
 ;;^UTILITY(U,$J,358.3,36970,1,4,0)
 ;;=4^D68.52
 ;;^UTILITY(U,$J,358.3,36970,2)
 ;;=^5002359
 ;;^UTILITY(U,$J,358.3,36971,0)
 ;;=D68.59^^169^1864^15
 ;;^UTILITY(U,$J,358.3,36971,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36971,1,3,0)
 ;;=3^Primary Thrombophilia NEC
 ;;^UTILITY(U,$J,358.3,36971,1,4,0)
 ;;=4^D68.59
 ;;^UTILITY(U,$J,358.3,36971,2)
 ;;=^5002360
 ;;^UTILITY(U,$J,358.3,36972,0)
 ;;=D68.61^^169^1864^2
 ;;^UTILITY(U,$J,358.3,36972,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36972,1,3,0)
 ;;=3^Antiphospholipid syndrome
 ;;^UTILITY(U,$J,358.3,36972,1,4,0)
 ;;=4^D68.61
 ;;^UTILITY(U,$J,358.3,36972,2)
 ;;=^185421
 ;;^UTILITY(U,$J,358.3,36973,0)
 ;;=D68.62^^169^1864^3
 ;;^UTILITY(U,$J,358.3,36973,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36973,1,3,0)
 ;;=3^Lupus anticoagulant syndrome
 ;;^UTILITY(U,$J,358.3,36973,1,4,0)
 ;;=4^D68.62
 ;;^UTILITY(U,$J,358.3,36973,2)
 ;;=^5002361
 ;;^UTILITY(U,$J,358.3,36974,0)
 ;;=Z85.810^^169^1865^3
 ;;^UTILITY(U,$J,358.3,36974,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36974,1,3,0)
 ;;=3^Personal history of malignant neoplasm of tongue
 ;;^UTILITY(U,$J,358.3,36974,1,4,0)
 ;;=4^Z85.810
 ;;^UTILITY(U,$J,358.3,36974,2)
 ;;=^5063438
 ;;^UTILITY(U,$J,358.3,36975,0)
 ;;=Z85.818^^169^1865^4
